Evidence map›Paper›PMID 28134280›Full record

ArticleScientific reports2017

Modulation of actin dynamics as potential macrophage subtype-targeting anti-tumour strategy.

Carlo Pergola, Katrin Schubert, Simona Pace, Jana Ziereisen, Felix Nikels, Olga Scherer, Stephan Hüttel, Stefan Zahler, Angelika M Vollmar, Christina Weinigel and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Coactosin-Like Protein Reduces Prostaglandin DAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  3. Article
  4. Article
  5. TiOJournal of nanobiotechnology · 2023
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Neutrophil Extracellular Trap Degradation by Differently Polarized Macrophage Subsets.Arteriosclerosis, thrombosis, and vascular biology · 2020
    Article
  14. Article
  15. Downregulation of calponin 2 contributes to the quiescence of lung macrophages.American journal of physiology. Cell physiology · 2019
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Carlo PergolaChair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University, Jena, Germany.
Katrin SchubertChair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University, Jena, Germany.
Simona PaceChair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University, Jena, Germany.
Jana ZiereisenChair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University, Jena, Germany.
Felix NikelsChair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University, Jena, Germany.
Olga SchererChair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University, Jena, Germany.
Stephan HüttelHelmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken, Germany.
Stefan ZahlerDepartment of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University, 81377 Munich, Germany.
Angelika M VollmarDepartment of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University, 81377 Munich, Germany.
Christina WeinigelInstitute of Transfusion Medicine, University Hospital Jena, Jena, Germany.
Silke RummlerInstitute of Transfusion Medicine, University Hospital Jena, Jena, Germany.
Rolf MüllerHelmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken, Germany.
Martin RaaschInstitute of Biochemistry II, University Hospital Jena, Jena, Germany.
Alexander MosigInstitute of Biochemistry II, University Hospital Jena, Jena, Germany.
Andreas KoeberleChair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University, Jena, Germany.
Oliver WerzChair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University, Jena, Germany.
Friedrich Schiller University Jena · DEJena University Hospital · DELudwig-Maximilians-Universität München · DEHelmholtz Centre for Infection Research · DEHelmholtz Institute for Pharmaceutical Research Saarland · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumour-associated macrophages mainly comprise immunosuppressive M2 phenotypes that promote tumour progression besides anti-tumoural M1 subsets. Selective depletion or reprogramming of M2 may represent an innovative anti-cancer strategy. The actin cytoskeleton is central for cellular homeostasis and is targeted for anti-cancer chemotherapy. Here, we show that targeting G-actin nucleation using chondramide A (ChA) predominantly depletes human M2 while promoting the tumour-suppressive M1 phenotype. ChA reduced the viability of M2, with minor effects on M1, but increased tumour necrosis factor (TNF)α release from M1. Interestingly, ChA caused rapid disruption of dynamic F-actin filaments and polymerization of G-actin, followed by reduction of cell size, binucleation and cell division, without cellular collapse. In M1, but not in M2, ChA caused marked activation of SAPK/JNK and NFκB, with slight or no effects on Akt, STAT-1/-3, ERK-1/2, and p38 MAPK, seemingly accounting for the better survival of M1 and TNFα secretion. In a microfluidically-supported human tumour biochip model, circulating ChA-treated M1 markedly reduced tumour cell viability through enhanced release of TNFα. Together, ChA may cause an anti-tumoural microenvironment by depletion of M2 and activation of M1, suggesting induction of G-actin nucleation as potential strategy to target tumour-associated macrophages in addition to neoplastic cells.

Indexed as

Tumor MicroenvironmentActinsCaspasesCell Line, TumorCell MovementCells, CulturedCell SurvivalCytotoxicity, ImmunologicDepsipeptidesDose-Response Relationship, DrugHumansImmunomodulationMacrophage ActivationMacrophagesNeoplasmsProtein TransportActinsCaspaseschondramide ADepsipeptidesTumor Necrosis Factor-alpha

Identifiers

PMID28134280
PMCPMC5278352
OpenAlexW2581087986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.